United Therapeutics (NASDAQ:UTHR) CEO Sells $1,870,200.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $467.55, for a total transaction of $1,870,200.00. Following the transaction, the chief executive officer owned 130 shares in the company, valued at approximately $60,781.50. The trade was a 96.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Price Performance

United Therapeutics stock traded up $4.67 during midday trading on Tuesday, reaching $476.59. The company’s stock had a trading volume of 599,870 shares, compared to its average volume of 591,927. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $485.32. The stock has a market capitalization of $20.52 billion, a P/E ratio of 18.06, a PEG ratio of 4.96 and a beta of 0.77. The stock’s 50-day simple moving average is $433.93 and its 200-day simple moving average is $351.26.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. During the same period in the previous year, the firm posted $6.39 earnings per share. The firm’s quarterly revenue was up 6.8% on a year-over-year basis. As a group, equities research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently commented on UTHR shares. HC Wainwright raised their target price on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. UBS Group raised their price objective on United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Royal Bank Of Canada increased their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Morgan Stanley set a $447.00 price objective on shares of United Therapeutics in a research report on Wednesday, October 29th. Finally, Cantor Fitzgerald upped their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research note on Wednesday, September 10th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $503.90.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Darwin Global Management Ltd. acquired a new position in United Therapeutics during the third quarter worth $317,617,000. Norges Bank acquired a new position in United Therapeutics during the 2nd quarter worth $136,453,000. Invesco Ltd. lifted its holdings in United Therapeutics by 90.2% during the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after buying an additional 419,588 shares in the last quarter. AQR Capital Management LLC boosted its position in United Therapeutics by 40.1% in the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after buying an additional 364,713 shares during the last quarter. Finally, Nuveen LLC bought a new stake in shares of United Therapeutics during the first quarter worth $83,533,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.